Medical
-
Johnson & Johnson has decided not to exercise an option acquired in a 2020 agreement with Pulmatrix for development and commercialization of Pulmatrix’s portfolio of inhaled narrow spectrum kinase inhibitors (NSKIs), including PUR1800. J&J’s Lung… Read more . . .
-
AIM ImmunoTech has announced that it will definitely advance an intranasal formulation of its Ampligen rintatolimod into a Phase 2 trial after the initial dose tested in a Phase 1 study showed no safety problems.… Read more . . .
-
Intravacc has announced that a pre-clinical study of its intranasal outer membrane vesicle (OMV)-based recombinant spike protein (rSP) vaccine candidate against SARS-CoV-2 nose spray vaccine in hamsters and mice demonstrated complete protection. The company announced… Read more . . .
-
According to Union Therapeutics, a Phase 1 study of its UNI911 niclosamide solution met its primary endpoint, demonstrating “a strong safety profile” for both inhaled and intranasal delivery; the company said that the PK results were… Read more . . .
-
Neupharma, which is developing inhaled teicoplanin for the treatment of MRSA lung infections in CF patients in partnership with Rare Partners, has announced that a Phase 1 PK study of the formulation in cystic fibrosis… Read more . . .
-
The UK National Institute for Health Research has designated the PROTECT-V trial of Union Therapeutics’ UNI91103 niclosamide nasal spray for the treatment of COVID-19 in kidney patients as an Urgent Public Health (UPH) priority, the… Read more . . .
-
The University of Oxford has announced that it is recruiting subjects for a Phase I trial of a nasal spray version of its COVID-19 vaccine. The trial is expected to enroll 30 healthy adults aged… Read more . . .
-
According to Marinomed Biotech, a clinical trial of the company’s Inhaleen Carragelose iota-carageenan inhalation solution for the treatment of moderate COVID-19 is now underway. In April 2020, Marinomed announced that it had received funding for… Read more . . .
-
Altimmune announced that it has signed a manufacturing agreement with Summit Biosciences for a multidose version of Altimmune’s AdCOVID intranasal vaccine against COVID-19. The announcement comes shortly after Altimmune announced an agreement with Lonza for… Read more . . .
-
Galecto has announced that the company’s Phase 2b GALACTIC-1 study of GB0139 (formerly TD139) galectin-3 inhibitor DPI for the treatment of idiopathic pulmonary fibrosis (IPF) will discontinue the higher dose (10 mg) arm and will limit… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland